NCT00639691View on ClinicalTrials.gov

A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Asthma
Interventions
BIOLOGICAL

omalizumab

sc

Trial Locations (1)

Unknown

Novartis Investigative Site, Montreal

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00639691 - A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy | Biotech Hunter | Biotech Hunter